Nodal Marginal Zone Lymphoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-NODAL-MZL |
|---|---|
| Type | Disease |
| Aliases | NMZLНодальна лімфома маргінальної зони |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-MZL-2024 SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9699/3 |
|---|---|
| icd_10 | C83.0 |
| who_classification | Mature B-cell neoplasms — Nodal marginal zone lymphoma per WHO 5th ed. |
Notes
Treatment paradigm mirrors FL: GELF-style criteria for active treatment; W&W for asymptomatic low-burden. No specific etiologic agent identified (so antiviral pathway not relevant).
Used By
Actionability
BMA-MYD88-L265P-NODAL-MZL- MYD88 L265P found in ~5-10% of MZL (more in lymphoplasmacytoid variants; rare in classic...
Algorithms
ALGO-NMZL-1L- ALGO-NMZL-1LALGO-NMZL-2L- ALGO-NMZL-2L
Disease
DIS-HCV-MZL- HCV-associated Marginal Zone Lymphoma
Indication
IND-NMZL-1L-BR- IND-NMZL-1L-BRIND-NMZL-1L-HCV-POSITIVE- IND-NMZL-1L-HCV-POSITIVEIND-NMZL-1L-WATCH- IND-NMZL-1L-WATCHIND-NMZL-2L-BR- IND-NMZL-2L-BR
Questionnaires
QUEST-NODAL-MZL-1L-STUB- Nodal Marginal Zone Lymphoma — first line
Red flag
RF-NMZL-FRAILTY-AGE- Age >80 OR ECOG ≥3 with comorbidity AND asymptomatic NMZL (no GELF criteria) — observatio...RF-NMZL-HIGH-RISK-BIOLOGY- TP53 mutation, NOTCH2 mutation (shared with SMZL), or aggressive histologic features — sh...RF-NMZL-INFECTION-SCREENING- HBV/HCV/HIV serology mandatory pre-rituximab; no NMZL-specific infectious driver establis...RF-NMZL-ORGAN-DYSFUNCTION- Renal dysfunction (CrCl <40 mL/min) — bendamustine clearance reduced; dose adjustment or...RF-NMZL-TRANSFORMATION-PROGRESSION- Histologic transformation to DLBCL (already wired through RF-FL-TRANSFORMATION-SUSPECT in...